Manufacture

Welcome to our Special Series E-book on Advanced Medicine!

Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.

Swiss firm Lonza is taking its investment in China to the next level with a manufacturing upgrade to its key site in Guangdong Province.

What are the challenges and best practices in quality control for difficult-to-inspect products?

Has pharma fully acknowledged the power of rapid-dissolve tablet technologies?

Precious metals-bearing catalysts are essential in some pharma processes – but, once they’re spent, they still hold value.

How to streamline a rapidly expanding field? Joe Garrity of Lonza discusses the pain points and easily missed fixes.

How can we maximize the potential and production of potentially life-saving therapies?

How a holistic approach to horseshoe crab sustainability will allow the industry to maintain stocks while protecting patients.

Lonza and Cytena combine expertise to allow biotherapeutic manufacturers to benefit from the advantages of Pichia pastoris as an expression system.